BR112017016021A2 - sequências oligonucleotídicas direcionadas ao fator de transcrição tsc22d4 para o tratamento de resistência à insulina - Google Patents
sequências oligonucleotídicas direcionadas ao fator de transcrição tsc22d4 para o tratamento de resistência à insulinaInfo
- Publication number
- BR112017016021A2 BR112017016021A2 BR112017016021-8A BR112017016021A BR112017016021A2 BR 112017016021 A2 BR112017016021 A2 BR 112017016021A2 BR 112017016021 A BR112017016021 A BR 112017016021A BR 112017016021 A2 BR112017016021 A2 BR 112017016021A2
- Authority
- BR
- Brazil
- Prior art keywords
- tsc22d4
- treatment
- insulin resistance
- transcription factor
- oligonucleotide sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15160259.6A EP3072969A1 (en) | 2015-03-23 | 2015-03-23 | Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance |
| EP15160259.6 | 2015-03-23 | ||
| PCT/EP2016/053050 WO2016150618A1 (en) | 2015-03-23 | 2016-02-12 | Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017016021A2 true BR112017016021A2 (pt) | 2018-03-20 |
Family
ID=52784935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017016021-8A BR112017016021A2 (pt) | 2015-03-23 | 2016-02-12 | sequências oligonucleotídicas direcionadas ao fator de transcrição tsc22d4 para o tratamento de resistência à insulina |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10676739B2 (https=) |
| EP (2) | EP3072969A1 (https=) |
| JP (1) | JP2018513841A (https=) |
| KR (1) | KR20170128348A (https=) |
| CN (1) | CN107278229A (https=) |
| BR (1) | BR112017016021A2 (https=) |
| DK (1) | DK3274455T3 (https=) |
| ES (1) | ES2837085T3 (https=) |
| MX (1) | MX384193B (https=) |
| RU (1) | RU2723091C2 (https=) |
| WO (1) | WO2016150618A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7289510B2 (ja) * | 2019-05-08 | 2023-06-12 | 国立大学法人高知大学 | 認知症治療薬のスクリーニング方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003503313A (ja) * | 1999-06-03 | 2003-01-28 | ジェシー エル エス オウ | 細胞増殖及び細胞死を変調する方法及び組成物 |
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| JP4869942B2 (ja) | 2003-12-11 | 2012-02-08 | ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド | インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４ |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| US7943306B2 (en) * | 2005-01-12 | 2011-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Gene expression signature for prediction of human cancer progression |
| WO2012158123A1 (en) | 2011-05-13 | 2012-11-22 | Agency For Science, Technology And Research | Compounds and methods for treating insulin resistance syndrome |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| EP2816356A1 (en) | 2013-06-17 | 2014-12-24 | Ruprecht-Karls-Universität Heidelberg | Treatment of insulin resistance through inhibitors of transcription factor TSC22D4 |
| RU2573450C1 (ru) * | 2014-08-11 | 2016-01-20 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Способ выявления генов-мишеней для диагностики и терапии лейкозов человека |
-
2015
- 2015-03-23 EP EP15160259.6A patent/EP3072969A1/en not_active Withdrawn
-
2016
- 2016-02-12 CN CN201680012500.4A patent/CN107278229A/zh active Pending
- 2016-02-12 MX MX2017012231A patent/MX384193B/es unknown
- 2016-02-12 KR KR1020177026584A patent/KR20170128348A/ko not_active Ceased
- 2016-02-12 EP EP16704222.5A patent/EP3274455B1/en active Active
- 2016-02-12 BR BR112017016021-8A patent/BR112017016021A2/pt not_active IP Right Cessation
- 2016-02-12 WO PCT/EP2016/053050 patent/WO2016150618A1/en not_active Ceased
- 2016-02-12 JP JP2017546667A patent/JP2018513841A/ja active Pending
- 2016-02-12 DK DK16704222.5T patent/DK3274455T3/da active
- 2016-02-12 ES ES16704222T patent/ES2837085T3/es active Active
- 2016-02-12 US US15/545,104 patent/US10676739B2/en active Active
- 2016-02-12 RU RU2017131900A patent/RU2723091C2/ru active
-
2020
- 2020-04-30 US US16/862,930 patent/US11053499B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX384193B (es) | 2025-03-12 |
| EP3274455B1 (en) | 2020-10-14 |
| RU2017131900A (ru) | 2019-04-23 |
| RU2017131900A3 (https=) | 2019-06-10 |
| CN107278229A (zh) | 2017-10-20 |
| KR20170128348A (ko) | 2017-11-22 |
| WO2016150618A1 (en) | 2016-09-29 |
| EP3274455A1 (en) | 2018-01-31 |
| US11053499B2 (en) | 2021-07-06 |
| US10676739B2 (en) | 2020-06-09 |
| RU2723091C2 (ru) | 2020-06-08 |
| CA2979115A1 (en) | 2016-09-29 |
| MX2017012231A (es) | 2018-01-30 |
| JP2018513841A (ja) | 2018-05-31 |
| ES2837085T3 (es) | 2021-06-29 |
| US20180023078A1 (en) | 2018-01-25 |
| EP3072969A1 (en) | 2016-09-28 |
| US20200255834A1 (en) | 2020-08-13 |
| DK3274455T3 (da) | 2020-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010329A (es) | Composicion farmaceutica que comprende empagliflozina y sus usos. | |
| MX2016015997A (es) | Preparacion y uso de beta-d-nicotinamida ribosido cristalina. | |
| BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| IL244668A0 (en) | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| CR20160582A (es) | Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada | |
| IL250016B (en) | Antisense oligonucleotides for the treatment of usher syndrome type 2 | |
| MX2015014512A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| BR112017028353A2 (pt) | anticorpos para cd40 com atividade agonista melhorada | |
| CO6571889A2 (es) | Antidotos anticoagulantes | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| HUE061596T2 (hu) | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben | |
| BR112014030416A2 (pt) | composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção. | |
| BR112015017251A2 (pt) | composições farmacêuticas compreendendo doadores de nitroxil | |
| BR112017011198A2 (pt) | composição farmacêutica ou nutracêutica com resistência contra a influência do etanol. | |
| BR112017025148A2 (pt) | composição farmacêutica ou nutracêutica com resistência contra a influência do etanol | |
| SI3170005T1 (sl) | Postopek napovedovanja izida zdravljenja z afliberceptom, pacienta, pri katerem obstaja sum, da je zbolel za rakom | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MA42287A (fr) | Traitement de patients atteints de diabète sucré de type 2 | |
| CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 | |
| BR112017001061A2 (pt) | combinação de vitamina d e zinco e seu uso | |
| DK2857037T3 (da) | Middel til forebyggelse og/eller behandling af perifere neuropatiske smerter forårsaget af anticancerlægemiddel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2761 DE 05-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |